Crawley Lab

Angela M. Crawley profile picture

Contact Information

Angela M. Crawley, Ph.D.
613-737-8673
acrawley@ohri.ca

Fax: 613-737-8803
Research Administrative Assistant:
Heidi Hickey, hhickey@ohri.ca
613-737-8899 x72794

ORCID logo https://orcid.org/0000-0002-7453-7922

Angela M. Crawley

Scientist, Chronic Disease Program
Ottawa Hospital Research Institute
Assistant Professor, Biochem., Microbiol., and Immunol.
University of Ottawa
Adjunct Professor, Biology
Carleton University

Research Interests

  • Identify the underlying mechanisms of CD8+ T-cell dysfunction in HCV mono- and HIV-HCV co-infection. The function of CD8+ T-cells in the blood and liver are being evaluated. Both host and viral factors that contribute to bulk CD8+ T-cell impairment are being studied.
  • Evaluate innate and adaptive immunity interactions in HCV infection, specifically between macrophage subsets, liver-resident macrophages (Kupffer cells) and CD8+ T-cells.
  • Evaluate the effects of chronic HCV infection on responses to routine vaccination (e.g. seasonal flu and Hepatitis B vaccines).
  • Explore the therapeutic potential of soluble cytokine receptors in the prevention and treatment of disease.

Brief Biography

Dr. Crawley has been with the Chronic Diseases Program at the Ottawa Hospital Research Institute since April 2012. In addition to being a Scientist with the OHRI, she is also an Assistant Professor at the University of Ottawa and an Adjust Professor at Carleton University, where she teaches immunology at the undergraduate, graduate and medical school levels. She teaches these courses in both English and French. Dr. Crawley has earned 2 salary awards: a CIHR New Investigator Award and an Ontario HIV Treatment Network (OHTN) Junior Investigator Development Award. Her research is funded by the OHTN, Canadian Foundation of AIDS Research and the J.P. Bickell Medical Research Foundation.

Dr. Crawley received a B.Sc. in Microbiology and Immunology from McGill University in Montreal, Quebec (Canada) in 1999. In 2004 she completed a Ph.D. in Immunology with Dr. Bruce N. Wilkie in the Dept. of Pathobiology at the University of Guelph’s Ontario Veterinary College (Guelph, Ontario, Canada). Dr. Crawley then trained as a postdoctoral fellow in Dr. Jonathan B. Angel’s laboratory at the Ottawa Hospital Research Institute, and published 10 peer-reviewed scientific research and review articles on the immunopathogenesis of HIV infection. Dr. Crawley was funded by an Ontario HIV Treatment Network (OHTN) Fellowship award and awarded a University of Ottawa Faculty of Medicine Postdoctoral Award of Excellence (2007).

For more information including a list of courses taught, please visit: http://www.crawleylab.ca/

Selected Publications

    Last 3 years:

    2021
    1. Ali H., Caballero R., Iqbal S., Gajnayaka N., Ahmed D., Dong S., Vranjkovic V., Crawley AM., Angel JB., Cassol E., Kumar A. Selective killing of human M1 macrophages by Smac mimetics alone and M2 macrophages by Smac mimetics and caspase inhibition. J. Leuk. Biol. 2021.

    2020
    2. Côté, SC., Burke Schinkel, SC., Berthoud TK., Barros PO., Sanchez-Vidales M., Davidson AM., Crawley AM., Angel JB. IL-7 induces sCD127 release and mCD127 downregulation in human CD8+ T cells by distinct yet overlapping mechanisms, both of which are impaired in HIV infection. Eur. J. Immunol., 2020. 50:1537-49.

    3. Li J., Casey JL., Greenwald ZR., Yasseen AS., Dickie M., Feld JJ., Cooper CL., Crawley AM. The 9th Canadian Symposium on Hepatitis C Virus: Advances in HCV research and treatment towards elimination. Can. Liv. J. 2020.

    4. Okwor CIA., Oh JS., Crawley AM., Cooper CL., Lee SH. Expression of inhibitory receptors on T and NK cells defines immunological phenotypes of HCV patients with advanced liver fibrosis. (iScience, 2020. 23(9): 101513 - impact factor: 5.8).

    5. Odai KG., O’Dwyer C., Steenbergen R., Shaw T., Renner T., Ghorbani P., Langlois M-A., Crawley AM., Russell RS., Pezacki J., Tyrrell LD., Fullerton MD. In vitro hepatitis C virus infection and hepatic choline metabolism. Viruses, 12(1). pii: E108, 2020.

    2019
    6. Vranjkovic A., Deonarine F., Angel JB., Cooper CL., Crawley AM. Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease. Frontiers Immunol., 10:1926, 2019.

    7. Doyle MA., Lee T., Singer J., Crawley AM., Klein M., Cooper CL. Evaluation of safety and effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch followed by Ledipasvir Sofosbuvir HCV Therapy in HIV-HCV Co-Infection. Open Forum Infectious Diseases 6(7). pii: ofz318 2019.

    8. Ahmed F., Ibrahim A., Cooper CL., Kumar A., Crawley AM. Chronic Hepatitis C Virus Infection Impairs M1 Macrophage Differentiation and Contributes to CD8 + T-Cell Dysfunction. Cells 2019, 8:374 - Special Issue: Hepatitis C Virus and Host Interactions, by invitation.

    9. Doyle M-A., Mulvihill E., Galanakis C., Crawley AM., Cooper CL. Influence of Ribavirin and the Cirrhotic State on Metabolic Measures in Hepatitis C Direct Acting Antiviral Treatment Recipients. Cells 2019, 8:252 - Special Issue: Hepatitis C Virus and Host Interactions, by invitation.

    Diseases, conditions and populations of interest





    Research and clinical approaches